%0 Journal Article
%A Koerber, Stefan A
%A Sprute, Katharina
%A Kratochwil, Clemens
%A Winter, Erik
%A Haefner, Matthias F
%A Katayama, Sonja
%A Schlampp, Ingmar
%A Herfarth, Klaus
%A Kopka, Klaus
%A Afshar-Oromieh, Ali
%A Zschaebitz, Stefanie
%A Holland-Letz, Tim
%A Choyke, Peter L
%A Jaeger, Dirk
%A Hohenfellner, Markus
%A Haberkorn, Uwe
%A Debus, Juergen
%A Giesel, Frederik
%T Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer.
%J European journal of nuclear medicine and molecular imaging
%V 48
%N 1
%@ 1619-7089
%C Heidelberg [u.a.]
%I Springer-Verl.
%M DKFZ-2020-01038
%P 143-151
%D 2021
%Z 2021 Jan;48(1):143-151
%X First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic disease that may be amenable to image-guided radiotherapy. The current study classifies the type and localization of metastases and the clinical outcome of PSMA-PET/CT-guided radiotherapy to selected metastases.Between 2011 and 2019, 86 patients with recurrent, oligometastatic prostate carcinoma were identified by PSMA-PET/CT and were treated with image-guided radiotherapy of their metastases. Sites of relapse were characterized, and the primary endpoint overall survival (OS), biochemical progression-free survival (bPFS), and androgen deprivation therapy (ADT)-free survival were tabulated.In total, 37
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32405735
%R 10.1007/s00259-020-04777-z
%U https://inrepo02.dkfz.de/record/154800